Revenue and Related Matters |
Note 3. Revenue and Related Matters Revenue from Contracts with Customers The Company’s customers primarily consist of entities engaged in life sciences research that pursue the discovery and development of new drugs for a variety of neurologic, oncologic, cardiovascular, infectious disease, and other protein biomarkers associated with diseases. The Company’s customer base includes pharmaceutical, biotechnology, contract research organizations, academic, and government institutions. Disaggregated Revenue When disaggregating revenue, the Company considers all of the economic factors that may affect its revenues. The following table disaggregates the Company’s revenue from contracts with customers by geography, based on the location products and services are consumed, and revenue type (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended March 31, 2024 | | Three Months Ended March 31, 2023 | | North America | | EMEA | | Asia Pacific | | Total | | North America | | EMEA | | Asia Pacific | | Total | Product revenue: | | | | | | | | | | | | | | | | | | | | | | | | Instruments | $ | 408 | | $ | 1,269 | | $ | 869 | | $ | 2,546 | | $ | 2,144 | | $ | 1,981 | | $ | 1,135 | | $ | 5,260 | Consumable and other products | | 10,242 | | | 4,041 | | | 2,841 | | | 17,124 | | | 7,457 | | | 4,940 | | | 1,630 | | | 14,027 | Total | $ | 10,650 | | $ | 5,310 | | $ | 3,710 | | $ | 19,670 | | $ | 9,601 | | $ | 6,921 | | $ | 2,765 | | $ | 19,287 | | | | | | | | | | | | | | | | | | | | | | | | | Service revenue: | | | | | | | | | | | | | | | | | | | | | | | | Service-type warranties | $ | 1,637 | | $ | 852 | | $ | 194 | | $ | 2,683 | | $ | 1,557 | | $ | 706 | | $ | 135 | | $ | 2,398 | Research services | | 5,762 | | | 2,802 | | | 127 | | | 8,691 | | | 5,190 | | | 234 | | | 115 | | | 5,539 | Other services | | 318 | | | 248 | | | 27 | | | 593 | | | 381 | | | 257 | | | 4 | | | 642 | Total | $ | 7,717 | | $ | 3,902 | | $ | 348 | | $ | 11,967 | | $ | 7,128 | | $ | 1,197 | | $ | 254 | | $ | 8,579 | | | | | | | | | | | | | | | | | | | | | | | | | Collaboration and license revenue: | | | | | | | | | | | | | | | | | | | | | | | | Total | $ | 67 | | $ | 88 | | $ | — | | $ | 155 | | $ | 368 | | $ | — | | $ | — | | $ | 368 |
For the three months ended March 31, 2024, no customer accounted for more than 10% of the Company’s total revenues and for the three months ended March 31, 2023, one customer accounted for more than 10% of the Company’s total revenues. At March 31, 2024 and December 31, 2023, one customer accounted for more than 10% of the Company’s gross accounts receivable. Eli Lilly and Company Service Revenue Agreements On February 25, 2022, the Company entered into a Master Collaboration Agreement with Eli Lilly and Company (“Lilly”) establishing a framework for future projects focused on the development of Simoa immunoassays (the “Lilly Collaboration Agreement”). The Company also entered into a statement of work under the Lilly Collaboration Agreement to perform assay research and development services within the field of Alzheimer’s disease. Under the statement of work, the Company receives $1.5 million per calendar quarter, which began in the first quarter of 2022. The statement of work automatically renews on a quarterly basis until Lilly provides a termination notice in accordance with the terms of the Lilly Collaboration Agreement. As of March 31, 2024, the Lilly Collaboration Agreement and the statement of work were still in effect. Concurrent with the execution of the Lilly Collaboration Agreement, the Company entered into a Technology License Agreement (the “Lilly License”) under which Lilly granted the Company a non-exclusive license to Lilly’s proprietary p-Tau 217 antibody technology for use in research use only products and services and future in vitro diagnostics (“IVD”) applications within the field of Alzheimer’s disease. In consideration of the Lilly License, the Company paid an upfront fee, is required to make milestone payments based on the achievement of predetermined regulatory and commercial events, and will pay royalties on net sales of licensed products. The Company recognized $1.5 million of revenue from the Lilly Collaboration Agreement during the three months ended March 31, 2024 and 2023. Contract Assets There were no contract assets as of March 31, 2024 or December 31, 2023. Deferred Revenue During the three months ended March 31, 2024 and 2023, the Company recognized $2.7 million and $2.4 million of revenue, respectively, related to its deferred revenue balance at January 1 of each such period. Remaining Performance Obligations As of March 31, 2024, the aggregate amount of transaction prices allocated to performance obligations that were not yet satisfied, or were partially satisfied, was $11.2 million. Of this amount, $10.2 million is expected to be recognized as revenue in the next 12 months, with the remainder expected to be recognized thereafter. The $11.2 million primarily consists of amounts billed for undelivered services related to initial and extended service-type warranties and research services. Costs to Obtain a Contract Changes in costs to obtain a contract were as follows (in thousands): | | | | | | | 2024 | | 2023 | Balance at December 31 of prior year | $ | 288 | | $ | 377 | Capitalization of costs to obtain a contract | | 97 | | | 197 | Recognition of costs to obtain a contract | | (95) | | | (191) | Balance at March 31 | $ | 290 | | $ | 383 |
The Company evaluates potential impairment of these amounts at each balance sheet date, and no related impairments were recorded during the three months ended March 31, 2024 and 2023. Grant Revenue All of the Company's grant revenue is generated within North America. NIH Grant On September 21, 2022, the Company and the National Institutes of Health (the “NIH”), an agency of the U.S. Department of Health and Human Services, entered into a contract (the “NIH Grant”) with a total award value of $1.7 million. The NIH granted the Company funding in support of the development of certain point-of-care diagnostic technologies through collaborative efforts. Grant funding is to be used solely for activities related to the point-of-care diagnostic device development project and the contract period runs through August 2025. Receipt of the award value occurs throughout the term of the contract period and after the Company submits for reimbursement of activities related to the grant. As of March 31, 2024, the Company had received $0.8 million of the total award value. During the three months ended March 31, 2024 and 2023, grant revenue recognized and research and development expenses incurred were not material. ADDF Grant On March 24, 2022, the Company and the Alzheimer’s Drug Discovery Foundation (the “ADDF”) entered into a contract (the “ADDF Grant”) with a total funding value of $2.3 million. The ADDF is a charitable venture philanthropy entity that granted the Company funding in support of certain activities for the development of an IVD test for early detection of Alzheimer's disease. The ADDF Grant restricts the Company’s use of the granted funds solely for activities related to the Company’s Alzheimer’s diagnostic test development project and the contract period runs through June 2024. Receipt of the contract funding was subject to achievement of pre-defined milestones, and as of December 31, 2023, the Company had received the total funding value of $2.3 million. During the three months ended March 31, 2024 and 2023 grant revenue recognized and research and development expenses incurred were not material. As of March 31, 2024, the Company had $1.0 million of deferred revenue related to the ADDF Grant.
|